These findings demonstrate a remarkable synergic treatment effect capable of eliciting p53-, β-catenin-, and MGMT-dependent apoptotic cell death (Enlarge font of words in Fig. 8) and may also be highly clinically relevant to chemo-regimens for various CRC subtype-based interventions, which can be tailored to a patient’s individual requirements. Here, TP53 is linked to colorectal carcinoma.